Treatment of Episcleritis and Scleritis
The treatment of episcleritis can usually be strictly supportive, although in some instances systemic nonsteroidal anti-inflammatory drugs (NSAIDs) are indicated. Diffuse and nodular scleritis can usually be effectively treated in the same way, that is, with NSAIDs. If NSAID therapy fails, systemic corticosteroid therapy is indicated, provided there are no contraindications to this approach. If the scleritis continues to recur with each attempt to discontinue steroid therapy after 6 months of treatment, immunomodulatory therapy (IMT) or biologic response modifiers (BRM) should be considered. The same applies for patients who develop serious steroid-induced side effects. Patients with an established, potentially lethal systemic vasculitis as the cause of scleritis (e.g., polyarteritis nodosa or granulomatosis with polyangiitis (Wegener)), and patients with necrotizing scleritis, always require treatment with IMT or BRM.
KeywordsSystemic Lupus Erythematosus Rheumatoid Arthritis Patient Juvenile Idiopathic Arthritis Systemic Lupus Erythematosus Patient Polyarteritis Nodosa
- 1.Watson PG, Hazleman DL, Pavesio C, Green WR. The sclera and systemic disorders. London: Butterworth Heinemann; 2004, Chap 12. p. 291.Google Scholar
- 4.Fauci AS. Vasculitis. In: Parker CW, editor. Clinical Immunology. Philadelphia: W.B. Saunders; 1980. p. 473–519.Google Scholar
- 7.Jones P, Jayson MIV. Rheumatoid arthritis of the eye. Proc Royal Soc Med. 1973;66:1161.Google Scholar
- 8.Foster CS. Nonsteroidal anti-inflammatory and immunosuppressive agents. In: Lambert DW, Potter DE, editors. Clinical ophthalmic pharmacology. Boston: Little Brown; 1987. p. 173–92.Google Scholar